Share

Profile & Fundamentals

AbbVie Profile & Fundamentals

Name: AbbVie financial chart data preview
Creator: iPulse AI
License: https://ipulseai.com/terms

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables

Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Jump directly to any section

Company and Market Context

Company Profile & Ownership

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Company profile record

AbbVie Inc

Common Stock · Health Care · Biotechnology

Official website

Company

Company / asset: AbbVie Inc
Security type: Common Stock
Sector: Health Care
Industry: Biotechnology
HQ: 🇺🇸 United States
Head office: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

Leadership & scale

Full-time employees: 57K
Fiscal year end: December
IPO date: 2013-01-02

Fundamentals snapshot

Updated 2026-09-14

Market Cap: USD 467.5B
P/E: 74.0x
Revenue (Q2 26): USD 17.0B
Profit (Q2 26): USD 3.6B
Dividend Yield: 1.8%
Revenue (FY 25): USD 61.2B
Shares in public float: 1.8B
Insider ownership: 0.11%

Reporting & identifiers

Symbol: ABBV.NYSE
Listing: 🇺🇸 United States | Dividend Tax: 30%
Ticker Currency: USD
Income Statement Currency: USD
Balance Sheet Currency: USD
Cash Flow Currency: USD
EPS Currency: USD
Contract Type: SPOT
ISIN: US00287Y1091
Asset ID: equity_bdad71da-994f-5fe7-bb1b-f99ddc7a4cbc

Ownership

Shares Outstanding

Shares outstanding

Annual reported shares outstanding. Values in shares.

Top holders

BlackRock Inc150,698,125 shares · 8.53% · Reported 2026-03-31
Vanguard Capital Management, LLC114,880,324 shares · 6.50% · Reported 2026-03-31
State Street Corp81,217,516 shares · 4.60% · Reported 2026-03-31
JPMorgan Chase & Co56,741,691 shares · 3.21% · Reported 2026-03-31
Vanguard MStar Total Stk Mkt Idx Invest56,259,925 shares · 3.18% · Reported 2026-07-31
Vanguard Portfolio Management, LLC49,523,078 shares · 2.80% · Reported 2026-03-31
Geode Capital Management, LLC46,737,581 shares · 2.64% · Reported 2026-03-31

View more holders (8)

Vanguard 500 Index Investor46,381,842 shares · 2.62% · Reported 2026-07-31
Morgan Stanley - Brokerage Accounts38,016,774 shares · 2.15% · Reported 2026-03-31
Capital Research Global Investors30,101,551 shares · 1.70% · Reported 2026-06-30
NORGES BANK25,554,538 shares · 1.45% · Reported 2026-06-30
Bank of America Corp23,936,943 shares · 1.35% · Reported 2026-03-31
iShares Core S&P 500 ETF23,527,465 shares · 1.33% · Reported 2026-08-31
Fidelity 500 Index22,846,482 shares · 1.29% · Reported 2026-07-31
FMR Inc21,762,703 shares · 1.23% · Reported 2026-03-31

Earnings, Profitability & Valuation

Earnings & Revenue

AI Review

The company's financial picture shows a major split between official accounting profits and actual cash generation. On paper, net income looks very low, which has created a scary-looking price-to-earnings ratio. However, this is just an illusion caused by one-time accounting write-offs from recent business purchases. In reality, the company's actual sales are growing steadily, and it generates over twenty billion dollars in real, usable cash flow each year. All assessments agree that the company's new immunology drugs have successfully replaced its older blockbuster drug, completely beating expectations. However, there is some disagreement on how much future profits might be limited by government price controls and rising interest costs. Overall, the core business remains incredibly strong, and the confusing accounting numbers are hiding a highly profitable cash-generating machine.

Revenue, Net Income, and Free Cash Flow

Revenue
Free cash flow
Net income

Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

Published P/E

Published valuation snapshots. Trailing four-quarter earnings where available; annual earnings otherwise. Non-positive earnings are omitted. Values in times earnings.

Profitability & Margins

AI Review

The company boasts elite profitability, with gross margins holding steady at an impressive seventy percent. This means the actual cost to manufacture its complex biological treatments is very low, providing a powerful shield against inflation and rising supply chain costs. While operating margins have looked volatile recently, this is entirely due to the temporary, lumpy expenses of integrating new acquisitions. Assessments agree that the underlying profitability of the core business remains exceptionally strong. However, future outlooks clash regarding the ceiling on these margins. Some warn that government price negotiations and mandatory rebates will slowly squeeze profitability over the next few years. Others argue that increased manufacturing efficiency and the scaling of new blockbuster drugs will easily offset regulatory pressures, driving steady margin expansion as one-time acquisition costs fade away.

Profitability Margins

Gross margin
Operating margin
Net margin
Free cash flow margin

Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Sign in to check access View Base plan

Paywalled preview begins: Reported Data Tables — chart preview

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Reported Data Tables — chart preview

The following tables contain the same values as the financial charts above. Monetary values are USD; margins are percentages. Missing inputs are not estimated. Use is subject to the iPulse AI Terms of Service and applicable source rights.

Source: eodhd. Statement snapshots with chart transformations and ratios calculated by iPulse AI. Snapshot retrieved 2026-09-15.

Annual earnings and profitability
Period end	Revenue	Free cash flow	Net income	Gross margin	Operating margin	Net margin	Free cash flow margin
2016-12-31	25,638,000,000	6,562,000,000	5,953,000,000	77.25	36.43	23.22	25.59
2017-12-31	28,216,000,000	9,431,000,000	5,309,000,000	75.05	33.83	18.82	33.42
2018-12-31	32,753,000,000	12,789,000,000	5,687,000,000	76.44	19.49	17.36	39.05
2019-12-31	33,266,000,000	12,772,000,000	7,882,000,000	77.64	39.03	23.69	38.39
2020-12-31	45,804,000,000	16,790,000,000	4,616,000,000	66.41	24.81	10.08	36.66
2021-12-31	56,197,000,000	21,990,000,000	11,542,000,000	68.96	31.89	20.54	39.13
2022-12-31	58,054,000,000	24,248,000,000	11,836,000,000	70	31.21	20.39	41.77
2023-12-31	54,318,000,000	22,062,000,000	4,863,000,000	62.42	23.49	8.95	40.62
2024-12-31	56,334,000,000	17,832,000,000	4,278,000,000	69.99	16.22	7.59	31.65
2025-12-31	61,160,000,000	17,816,000,000	4,226,000,000	70.24	32.85	6.91	29.13

Published valuation snapshots
Period end	P/E (times earnings)	Earnings basis
2025-12-31	95.92	Trailing four quarters
2024-12-31	73.65	Trailing four quarters
2023-12-31	56.47	Trailing four quarters
2022-12-31	24.28	Annual net income
2021-12-31	20.86	Annual net income

Shares outstanding — chart values
Reporting date	Shares outstanding
2017-01-01	1,602,000,000
2018-01-01	1,481,301,000
2019-01-01	1,485,000,000
2020-01-01	1,781,000,000
2021-01-01	1,778,000,000
2022-01-01	1,778,000,000
2023-01-01	1,772,000,000
2024-01-01	1,773,000,000
2025-01-01	1,774,000,000
2026-01-01	1,771,000,000

End of the paywalled preview

The excerpt from Reported Data Tables — chart preview to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Earnings, Profitability & Valuation
- Complete profitability ratios
- EPS history and estimate comparisons
- Execution vs expectations
- Annual and quarterly financial views
Capital Expenditure & R&D
- Capital allocation AI review
- Annual capital expenditure
- Investment intensity trends
- Capex and R&D intensity indicators
Balance Sheet
- Balance sheet AI review
- Assets, debt and equity
- Capital structure
- Liquidity and leverage
- Retained earnings
Dividends & Actions
- Cash dividends paid
- Dividend indicators
- Buybacks and issuance
- Combined shareholder returns
- Available corporate actions
Company Events
- Dated insider transactions
- Material company activity

Explore complete public research examples

These public assets show the complete asset profiles, fundamental datasets and analysis. Their findings concern those assets, not this report.